Allogene Therapeutics Stock Alpha and Beta Analysis
| ALLO Stock | USD 1.91 0.16 7.73% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Allogene Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Allogene Therapeutics over a specified time horizon. Remember, high Allogene Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Allogene Therapeutics' market risk premium analysis include:
Beta 2.56 | Alpha (0.56) | Risk 5.08 | Sharpe Ratio (0.09) | Expected Return (0.48) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Allogene |
Allogene Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Allogene Therapeutics market risk premium is the additional return an investor will receive from holding Allogene Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Allogene Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Allogene Therapeutics' performance over market.| α | -0.56 | β | 2.56 |
Allogene Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Allogene Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Allogene Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Allogene Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Allogene Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Allogene Therapeutics shares will generate the highest return on investment. By understating and applying Allogene Therapeutics stock market price indicators, traders can identify Allogene Therapeutics position entry and exit signals to maximize returns.
Allogene Therapeutics Return and Market Media
The median price of Allogene Therapeutics for the period between Fri, Sep 20, 2024 and Thu, Dec 19, 2024 is 2.64 with a coefficient of variation of 12.51. The daily time series for the period is distributed with a sample standard deviation of 0.32, arithmetic mean of 2.57, and mean deviation of 0.26. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 36404 shares by Geoffrey Parker of Allogene Therapeutics at 2.84 subject to Rule 16b-3 | 10/21/2024 |
2 | Disposition of 24428 shares by Smith Lillian of Allogene Therapeutics at 5.04 subject to Rule 16b-3 | 10/29/2024 |
3 | Allogene Therapeutics Inc Q3 2024 Everything You Need To Know Ahead Of Earnings | 11/06/2024 |
4 | AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains | 11/12/2024 |
5 | Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College ... | 11/18/2024 |
6 | Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug | 11/22/2024 |
7 | FDA Begins Review of Alnylams sNDA for Expanded Amvuttra Use | 11/26/2024 |
8 | Allogene Therapeutics Loses 23 percent Year to Date How to Play the Stock - Yahoo Finance | 12/02/2024 |
9 | ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD | 12/04/2024 |
10 | Disposition of 9136 shares by Messemer Deborah M. of Allogene Therapeutics at 2.18 subject to Rule 16b-3 | 12/09/2024 |
11 | Allogene Therapeutics Stock Drops Amidst Biotech Sector Decline | 12/12/2024 |
12 | Allogene Therapeutics Stock Drops Amid Biotech Sector Decline | 12/18/2024 |
About Allogene Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Allogene or other stocks. Alpha measures the amount that position in Allogene Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2010 | 2023 | 2024 (projected) | Interest Debt Per Share | 0.12 | 0.1 | 0.096 | Revenue Per Share | 0.28 | 6.05E-4 | 5.75E-4 |
Allogene Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Allogene Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Allogene Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Allogene Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Allogene Therapeutics. Please utilize our Beneish M Score to check the likelihood of Allogene Therapeutics' management manipulating its earnings.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Allogene Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Allogene Therapeutics Backtesting, Allogene Therapeutics Valuation, Allogene Therapeutics Correlation, Allogene Therapeutics Hype Analysis, Allogene Therapeutics Volatility, Allogene Therapeutics History and analyze Allogene Therapeutics Performance. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Allogene Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.